von Dr. Marcus Gereke
Statistik und Sichtungsnachweis dieser Seite findet sich am Artikelende
| [1.] Mag/Fragment 016 01 - Diskussion Zuletzt bearbeitet: 2014-03-10 12:00:44 Graf Isolan | Fehrenbach 2001, Fragment, Gesichtet, Mag, SMWFragment, Schutzlevel sysop, Verschleierung |
|
|
|
| Untersuchte Arbeit: Seite: 16, Zeilen: 1-5 |
Quelle: Fehrenbach_2001 Seite(n): 42, Zeilen: l.col: lines 11-18 |
|---|---|
| [Via] these cytokines, AECII might be involved in the induction of differentiation of basophil, eosinphil, and neutrophil granulocytes and maintenance of inflammatory reactions. Recent data support the idea that AECII have an accessory function in T lymphocyte activation (Zissel et al., 2000). This has been suggested on the basis of the findings that the cells bear MHC class-II molecules (Schneeberger et al., 1986). | Via these cytokines, AE2 cells might be involved in the induction of differentiation of basophil, eosinophil, and neutrophil granulocytes and maintenance of inflammatory reactions. Recent data support the idea that AE2 cells have an accessory function in T-lymphocyte activation [170]. This has been suggested on the basis of the finding that the cells bear receptors of MHC class II [171].
170. Zissel G, Ernst M, Rabe K, Papadopoulos T, Magnussen H, Schlaak M, Müller-Quernheim J: Human alveolar epithelial cells type II are capable of regulating T-cell activity. J Investig Med 2000, 48:66–75. 171. Schneeberger EE, DeFerrari M, Skoskiewicz MJ, Russell PS, Colvin RB: Induction of MHC-determined antigens in the lung by interferon-gamma. Lab Invest 1986, 55:138–144. |
The author adopts on pp. 13-16 an uninterrupted review of some 30 articles from Fehrenbach without indicating this source. This is the final part. After a short interruption, in which the author expands on Zissel and introduces a post-Fehrenbach (2005) article, the author continues to adopt two smaller text passages from Fehrenbach without indicating this source, ending on p. 17 line 7. |
|
| [2.] Mag/Fragment 016 16 - Diskussion Zuletzt bearbeitet: 2014-03-10 13:25:48 Hindemith | Fehrenbach 2001, Fragment, Gesichtet, Mag, SMWFragment, Schutzlevel sysop, Verschleierung |
|
|
|
| Untersuchte Arbeit: Seite: 16, Zeilen: 16-22 |
Quelle: Fehrenbach 2001 Seite(n): 42, Zeilen: l.col: 19-25 |
|---|---|
| Additionally, AECII were reported to inhibit lymphocyte proliferation in vitro without altering their activation state (Paine et al., 1991). Moreover, AECII derived TGF-β (Zissel et al., 2000) could indirectly inhibit T cell proliferation via blockade of activating factors, such as IL-2. In contrast, granulocyte macrophage-colony stimulating factor (GM-CSF) released at the basolateral surface of AECII could increase the potential of dendritic cells to induce T-cell proliferation (Christensen et al., 1995).
Christensen PJ, Armstrong LR, Fak JJ, Chen GH, McDonald RA, Toews GB, Paine R 3rd. Regulation of rat pulmonary dendritic cell immunostimulatory activity by alveolar epithelial cell-derived granulocyte macrophage colony-stimulating factor. Am J Respir Cell Mol Biol. 1995 Oct; 13 (4): 426-33. Paine R 3rd, Mody CH, Chavis A, Spahr MA, Turka LA, Toews GB. Alveolar epithelial cells block lymphocyte proliferation in vitro without inhibiting activation. Am J Respir Cell Mol Biol. 1991 Sep; 5 (3): 221-9. Zissel G, Ernst M, Rabe K, Papadopoulos T, Magnussen H, Schlaak M, Muller-Quernheim J. Human alveolar epithelial cells type II are capable of regulating T-cell activity. J Investig Med. 2000 Jan; 48 (1): 66-75. |
AE2 cells were reported to inhibit lymphocyte proliferation in vitro without altering their activation state [172]. AE2-cell-derived TGF-β [170] may indirectly inhibit T-cell proliferation via blockade of activating factors, such as IL-2. In contrast, GM-CSF released at the basolateral surface of AE2 cells may increase the potential of dendritic cells to induce T-cell proliferation [166].
166. Christensen PJ, Armstrong LR, Fak JJ, Chen GH, McDonald RA, Toews GB, Paine R III: Regulation of rat pulmonary dendritic cell immunostimulatory activity by alveolar epithelial cellderived granulocyte macrophage colony- stimulating factor. Am J Respir Cell Mol Biol 1995, 13:426–433. 170. Zissel G, Ernst M, Rabe K, Papadopoulos T, Magnussen H, Schlaak M, Müller-Quernheim J: Human alveolar epithelial cells type II are capable of regulating T-cell activity. J Investig Med 2000, 48:66–75. 172. Paine R III, Mody CH, Chavis A, Spahr MA, Turka LA, Toews GB: Alveolar epithelial cells block lymphocyte proliferation in vitro without inhibiting activation. Am J Respir Cell Mol Biol 1991, 5:221–229. |
The source is not mentioned here. |
|
| [3.] Mag/Fragment 016 27 - Diskussion Zuletzt bearbeitet: 2014-03-10 13:25:51 Hindemith | Fehrenbach 2001, Fragment, Gesichtet, Mag, SMWFragment, Schutzlevel sysop, Verschleierung |
|
|
|
| Untersuchte Arbeit: Seite: 16, Zeilen: 27-30 |
Quelle: Fehrenbach 2001 Seite(n): 34, Zeilen: l.col: 2-14 |
|---|---|
| The surface-active agent was characterized in numerous biochemical studies of BAL material and is now known to be composed of ∼90% lipids (with ∼80-90% phospholipids) and of ∼10% proteins (Griese, 1999). Unlike most other lipid-rich components of cells and organs, the surfactant lipids are characterized by an [unusually high level of satured [sic] fatty acid chains, such as the predominant dipalmitoylphosphatidylcholines, which contribute substantially to the unique properties of pulmonary surfactant (van Golde et al., 1994).]
Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J. 1999 Jun; 13 (6): 1455-76. Review. van Golde LMG, BatenburgJJ, Robertson B The pulmonary surfactant system. News in Physiol Sciences 1994, 9:13-20. |
This surface-active agent, termed surfactant, was characterised in numerous biochemical studies of bronchoalveolar lavage (BAL) material and is now known to be composed of ≈90% (mass) lipids (with ≈80-90% phospholipids) and of ≈10% proteins. Its composition may deviate greatly in pathologic states (for review, see eg [7]). Unlike most other lipid-rich components of cells and organs, the surfactant lipids are characterised by an unusually high level of saturated fatty acid chains, such as the predominant dipalmitoylphosphatidylcholines, which contribute substantially to the unique properties of pulmonary surfactant (for review, see eg [8]).
7. Griese M: Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999, 13:1455–1476. 8. Van Golde LMG, Batenburg JJ, Robertson B: The pulmonary surfactant system. News in Physiol Sciences 1994, 9:13–20. |
The source is not given. To be continued on the next page: Mag/Fragment_017_01 |
|
Letzte Bearbeitung dieser Seite: durch Benutzer:Hindemith, Zeitstempel: 20140310133837